We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Longeveron Inc is a biotechnology company developing cellular therapies for specific ageing-related and life-threatening conditions. It is involved in sponsoring clinical trials in the following indications: Aging Frailty, Alzheimer's disease, Metabolic Syndrome, Acute Respiratory Distress Syndrome ... Longeveron Inc is a biotechnology company developing cellular therapies for specific ageing-related and life-threatening conditions. It is involved in sponsoring clinical trials in the following indications: Aging Frailty, Alzheimer's disease, Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and Hypoplastic left heart syndrome (HLHS). Show more
MIAMI, April 18, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage biotechnology company developing cellular therapies for...
MIAMI, April 17, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage biotechnology company developing cellular therapies for...
MIAMI, April 15, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it has been accepted for...
MIAMI, April 11, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage biotechnology company developing cellular therapies for...
MIAMI, April 08, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening...
MIAMI, April 08, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that the Company’s CEO, Wa’el...
LOS ANGELES, Nov. 14, 2023 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to...
LOS ANGELES, Sept. 07, 2023 (GLOBE NEWSWIRE) -- via IBN – Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.37 | -17.7033492823 | 2.09 | 2.2897 | 1.68 | 507662 | 1.90965832 | CS |
4 | -1.92 | -52.7472527473 | 3.64 | 5.47 | 1.62 | 6733810 | 2.58865451 | CS |
12 | -3.74 | -68.4981684982 | 5.46 | 5.858 | 1.62 | 2324249 | 2.70305092 | CS |
26 | -17.48 | -91.0416666667 | 19.2 | 23.9 | 1.62 | 1241766 | 3.91711017 | CS |
52 | -26.78 | -93.9649122807 | 28.5 | 44 | 1.62 | 747987 | 7.93461017 | CS |
156 | -58.7 | -97.1532605098 | 60.42 | 450 | 1.62 | 1821172 | 140.3990542 | CS |
260 | -98.28 | -98.28 | 100 | 450 | 1.62 | 1776050 | 138.03245717 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions